Vanguard Group Inc. lifted its position in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 1.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,846,354 shares of the company's stock after purchasing an additional 90,673 shares during the period. Vanguard Group Inc. owned about 4.24% of Indivior worth $134,875,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently made changes to their positions in INDV. Wells Fargo & Company MN acquired a new position in shares of Indivior during the second quarter worth approximately $34,000. Qube Research & Technologies Ltd purchased a new stake in Indivior during the 3rd quarter worth about $41,000. Legal & General Group Plc purchased a new stake in shares of Indivior in the 3rd quarter valued at about $109,000. Alliancebernstein L.P. purchased a new position in shares of Indivior during the 2nd quarter valued at about $310,000. Finally, CJM Wealth Advisers Ltd. bought a new stake in shares of Indivior in the 2nd quarter worth approximately $312,000. 60.33% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, Craig Hallum started coverage on Indivior in a research note on Wednesday. They issued a "buy" rating and a $37.00 target price for the company.
Get Our Latest Stock Analysis on INDV
Indivior Stock Performance
Shares of INDV stock traded up $1.16 during mid-day trading on Wednesday, hitting $22.00. The company's stock had a trading volume of 335,715 shares, compared to its average volume of 121,639. Indivior PLC has a 52-week low of $14.38 and a 52-week high of $26.50. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of -1,099.45 and a beta of 0.46. The business has a 50-day moving average price of $19.87 and a 200 day moving average price of $18.52.
Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.15. The firm had revenue of $293.00 million during the quarter, compared to analyst estimates of $260.00 million. Indivior had a return on equity of 538.18% and a net margin of 0.18%. Equities research analysts predict that Indivior PLC will post 2.03 EPS for the current fiscal year.
Indivior Profile
(
Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
